Announcements

Matador Welcomes New Starters to Generis and CluePoints Teams

Matador Welcomes New Starters to Generis and CluePoints Teams

1st July 2022, Karuizawa, Japan:

Matador operates as an effective bridge between Japanese pharma and our overseas technology partners. This requires that we are bicultural, bilingual, suitably educated and of course capable at selling new ideas to our Japanese clients.

With very few Japanese university graduates able to speak English nor whom have an appreciation of the world outside Japan, Matador has been looking for new avenues to recruit highly motivated and capable young people to our team. We are delighted to welcome three new recently graduated colleagues, Nhung and Mai with MBAs and Lela with a Masters Degree.

Our new colleagues are from Vietnam and Georgia but impressed us with their exceptional English and Japanese skills. Immigrants are renowned for their incredible resilience, drive and business success and almost everyone at Matador is or has been an immigrant at some point. True to form, Lela, Mai and Nhung continue to amaze us with their attitudes. We are all certain that our clients and partners will delight in working with them and that they will be incredibly successful at Matador.

John Bolger, Matador CEO wrote :

Mai, Lela and Nhung impressed everyone at Matador from the very first meeting. Besides their command of both English and Japanese, they are exceptionally self-motivated and bring new skills and experiences to the team. Matador is one of only a very few Japanese companies to promote diversity and to publish an annual diversity report. In our report we expressed a recognition of the need to promote more women to management positions and this was a factor in our new recruits selecting to work with us at Matador. We already see that our new recruits are motivated to prove to us that they have what it takes. We all look forward to working with these three gifted young women and we hope that one day they may earn promotion to management positions.

Partner With Us

Offering overseas technology companies a low-risk, highly rewarding entry strategy to the Japanese pharma market